Key result
New trial protocol compares central versus peripheral BP-guided hypertension treatment to prevent target-organ damage.
Why the study?
It remains unknown whether hypertension treatment guided by central blood pressure parameters provides better cardiovascular protection than treatment guided by peripheral blood pressure.
Does pharmacological management of hypertension guided by central blood pressure targets reduce target organ damage compared to peripheral blood pressure targets?
RCT (n=84)
Open-label
1:1
Yes
Does pharmacological management of hypertension guided by central blood pressure targets reduce target organ damage compared to peripheral blood pressure targets?
This study protocol describes a randomized trial to determine whether central blood pressure-guided hypertension management provides superior cardiovascular protection compared to peripheral blood pressure-guided management.
No practice change warranted; RCT protocol leaves open whether central BP guidance reduces target organ damage.
Background Central blood pressure values and arterial stiffness have demonstrated to be a useful tool to stratify cardiovascular risk and also as a biomarker. A question that is still unanswered is if hypertension treatment guided by central blood pressure parameters will be even better to promote cardiovascular protection than peripheral one. Methods With this proposition we have designed an open prospective multicentric randomized protocol to compare central (G1) and peripheral (G2) blood pressure targets during 1 year follow-up concerning target organ damage (carotid intima media thickness, left ventricular hypertrophy, microalbuminuria and pulse wave velocity). OMRON 1100 will be used to access peripheral and Mobil O’Graph to access central blood pressure and pulse wave velocity, TOSHIBA Xsario with longitudinal linear transdutor 7.5 MHz bidimensional mode B to access carotid and left ventricular parameters. Expected Results This paper aims to describe methodological aspects concerning this research and we expect to find results to answer some open questions about hypertension treatment and cardiovascular protection.
No takes yet. Share an insight, caveat, or question.
Barroso et al. (2020) conducted an RCT in Arterial hypertension (n=84). Central blood pressure-guided treatment vs. Peripheral blood pressure-guided treatment was evaluated on Incidence of target-organ damage (carotid intima media thickness, left ventricular hypertrophy, microalbuminuria and pulse wave velocity). This paper describes the methodological protocol for a randomized trial comparing central versus peripheral blood pressure-guided hypertension treatment, and does not report clinical results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: